NCT02590952View on ClinicalTrials.gov

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Solid Tumor
Interventions
DRUG

Epitinib

The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02590952 - A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter